| SC 13G | 2024-02-06 | Lind Global Fund II LP | SEELOS THERAPEUTICS, INC. | 1,410,800 | - | EDGAR |
| SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | SEELOS THERAPEUTICS, INC. | 5,016,741 | 4.7% | EDGAR |
| SC 13G | 2022-07-08 | BlackRock Inc. | SEELOS THERAPEUTICS, INC. | 1,779,835 | 1.7% | EDGAR |
| SC 13G/A | 2022-02-10 | VANGUARD GROUP INC | SEELOS THERAPEUTICS, INC. | 5,146,483 | 5.0% | EDGAR |
| SC 13G | 2022-02-04 | BlackRock Inc. | SEELOS THERAPEUTICS, INC. | 6,563,054 | 6.4% | EDGAR |
| SC 13G | 2021-02-10 | VANGUARD GROUP INC | SEELOS THERAPEUTICS, INC. | 2,799,854 | 5.2% | EDGAR |
| SC 13G/A | 2021-01-15 | LIGAND PHARMACEUTICALS INC | SEELOS THERAPEUTICS, INC. | 2,224,000 | 4.1% | EDGAR |
| SC 13G/A | 2021-01-11 | Phoenixus AG | SEELOS THERAPEUTICS, INC. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2020-02-14 | ARMISTICE CAPITAL, LLC | SEELOS THERAPEUTICS, INC. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2020-02-14 | Altium Capital Management LP | SEELOS THERAPEUTICS, INC. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2020-02-12 | LIGAND PHARMACEUTICALS INC | SEELOS THERAPEUTICS, INC. | 2,224,000 | 8.1% | EDGAR |
| SC 13G/A | 2020-02-10 | CVI Investments, Inc. | SEELOS THERAPEUTICS, INC. | 491,126 | 1.8% | EDGAR |
| SC 13G | 2020-01-16 | Phoenixus AG | SEELOS THERAPEUTICS, INC. | 2,000,227 | 6.9% | EDGAR |
| SC 13G | 2019-04-15 | LIGAND PHARMACEUTICALS INC | SEELOS THERAPEUTICS, INC. | 2,224,000 | 10.0% | EDGAR |
| SC 13G | 2019-03-11 | CVI Investments, Inc. | SEELOS THERAPEUTICS, INC. | 690,563 | 9.9% | EDGAR |
| SC 13D/A | 2019-02-14 | ARMISTICE CAPITAL, LLC | SEELOS THERAPEUTICS, INC. | 318,730 | 5.0% | EDGAR |
| SC 13G/A | 2019-02-14 | Iroquois Capital Management, LLC | SEELOS THERAPEUTICS, INC. | 564,287 | 2.0% | EDGAR |
| SC 13G | 2019-02-08 | Altium Capital Management LP | SEELOS THERAPEUTICS, INC. | 228,676 | 6.6% | EDGAR |
| SC 13D | 2019-01-31 | Mehra Raj | SEELOS THERAPEUTICS, INC. | 3,081,546 | 49.5% | EDGAR |
| SC 13G/A | 2019-01-04 | SABBY MANAGEMENT, LLC | APRICUS BIOSCIENCES, INC. | 900,000 | 3.2% | EDGAR |